Selected article for: "development process and vaccine development process"

Author: Han, Seunghoon
Title: Clinical vaccine development
  • Document date: 2015_1_30
  • ID: 048eszf8_10
    Snippet: To meet society's need for safe and efficacious vaccines, the clinical vaccine development process has been refined for more than a century. Similar to that of chemical drugs, the clinical evaluation of a vaccine typically comprises three phases (Fig. 2) . The entire process takes 10-15 years and requires a budget of about 1 billion US dollars. A vaccine-specific developmental plan should be clearly established to ensure the efficient and success.....
    Document: To meet society's need for safe and efficacious vaccines, the clinical vaccine development process has been refined for more than a century. Similar to that of chemical drugs, the clinical evaluation of a vaccine typically comprises three phases (Fig. 2) . The entire process takes 10-15 years and requires a budget of about 1 billion US dollars. A vaccine-specific developmental plan should be clearly established to ensure the efficient and successful development before clinical evaluation. This includes the following contents: 1) identification of the target population (mostly healthy people with particular demographic characteristics) and their sociocultural factors; 2) risk assessment of the target disease and the vaccine itself; 3) understanding of the incidence of the target disease and environmental factors; 4) identification of the dose and route of administration; 5) plans to induce herd immunity; and 6) regulatory strategies. The general characteristics of clinical vaccine development compared with those of conventional drug development are summarized in Table 1 .

    Search related documents:
    Co phrase search for related documents
    • healthy people and risk assessment: 1
    • healthy people and target population: 1, 2
    • herd immunity and risk assessment: 1, 2, 3, 4, 5
    • herd immunity and target disease: 1, 2, 3
    • herd immunity and target population: 1, 2, 3, 4, 5, 6, 7
    • risk assessment and target disease: 1, 2, 3, 4
    • risk assessment and target disease risk assessment: 1
    • risk assessment and target population: 1, 2, 3, 4, 5
    • risk assessment and target population identification: 1
    • risk assessment and vaccine clinical evaluation: 1, 2
    • route dose and target population: 1
    • target population and vaccine clinical evaluation: 1